A clearer and wider path to accelerated approval may come into view after an upcoming public meeting on biomarkers and surrogate endpoint development.
The Sept. 5 event may lead to more guidance on the subject, something industry requested to gain more clarity about how they can be used, particularly as efforts to increase...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?